The Massachusetts-based biotech company led by CEO Stéphane Bancel went from relative obscurity to the Wall Street spotlight when its mRNA-based COVID-19 vaccine, developed with scientists from the U.S. National Institute of Allergy and Infectious Diseases, became the first in the U.S. to start human testing last March. The vaccine’s December 2020 greenlight by the U.S. Food and Drug Administration—and its subsequent worldwide distribution—vindicates the company’s focus on using mRNA genetic material to teach the human body to fight off COVID-19. Millions have received the shot, and Moderna is ramping up production to meet continued worldwide demand.
More Must-Reads From TIME
- Introducing the TIME100 Climate List
- Accenture’s Chief AI Officer on Why This Is a Defining Moment
- U.S. Doctors Can't Be Silent About Gaza: Column
- Inside COP28's Big 'Experiment'
- The Movie Wives Would Like a Word
- The 100 Must-Read Books of 2023
- The Top 100 Photos of 2023
- Want Weekly Recs on What to Watch, Read, and More? Sign Up for Worth Your Time
